

# Morton Aaron Scheinberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1562600/publications.pdf>

Version: 2024-02-01

70  
papers

1,237  
citations

430442

18  
h-index

395343

33  
g-index

73  
all docs

73  
docs citations

73  
times ranked

1547  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-two-Week Randomized, Double-blind, Placebo-controlled Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 1016-1027.	2.9	287
2	Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. <i>Current Rheumatology Reports</i> , 2017, 19, 37.	2.1	79
3	Yellow fever revaccination during infliximab therapy. <i>Arthritis Care and Research</i> , 2010, 62, 896-898.	1.5	59
4	The Enigmatic Development of Psoriasis and Psoriasiform Lesions During Anti-TNF Therapy: A Review. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 251-255.	1.6	58
5	A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1598-1602.	0.5	54
6	Leishmaniasis during anti-tumor necrosis factor therapy: Report of 4 cases and review of the literature (additional 28 cases). <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 152-157.	1.6	39
7	Development of Serum Sickness-Like Symptoms After Rituximab Infusion in Two Patients With Severe Hypergammaglobulinemia. <i>Journal of Clinical Rheumatology</i> , 2007, 13, 94-95.	0.5	34
8	Unexpected onset of psoriasis during infliximab treatment: Comment on the article by Beuthien et al. <i>Arthritis and Rheumatism</i> , 2005, 52, 1333-1334.	6.7	30
9	Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. <i>Clinical Rheumatology</i> , 2016, 35, 1719-1723.	1.0	27
10	Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report. <i>Case Reports in Dermatology</i> , 2017, 8, 262-266.	0.3	25
11	Belimumab in the treatment of systemic lupus erythematosus: An evidence based review of its place in therapy. <i>Autoimmunity Reviews</i> , 2018, 17, 103-107.	2.5	25
12	Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 701-711.	1.3	25
13	Alterations in Cytokine Profile and Dendritic Cells Subsets in Peripheral Blood of Rheumatoid Arthritis Patients before and after Biologic Therapy. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 334-342.	1.8	24
14	<i>Aspergillus fumigatus</i> Joint Infection: A Review. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 580-584.	1.6	24
15	Biosimilars in rheumatology: a view from Latin America. <i>Clinical Rheumatology</i> , 2012, 31, 1279-1280.	1.0	21
16	Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice. <i>Arthritis Research and Therapy</i> , 2014, 16, 501.	1.6	21
17	The effect of tocilizumab on the uptake of 18F-FDG-PET imaging in patients with adult-onset Still's disease. <i>Rheumatology</i> , 2010, 49, 1014-1016.	0.9	20
18	Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products. <i>MAbs</i> , 2018, 10, 166-176.	2.6	20

#	ARTICLE	IF	CITATIONS
19	Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100099.	2.0	20
20	The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept. <i>Clinical Rheumatology</i> , 2007, 27, 105-106.	1.0	18
21	Anticitrulline peptide antibodies (CCP3) in leprosy sera: a negative association. <i>Clinical Rheumatology</i> , 2008, 27, 515-516.	1.0	17
22	Real life experience on the effect of Belimumab in patients with active systemic lupus. <i>SpringerPlus</i> , 2014, 3, 758.	1.2	17
23	Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series. <i>Rheumatology and Therapy</i> , 2017, 4, 503-508.	1.1	15
24	Steroid-resistant sarcoidosis treated with baricitinib. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1259-1260.	0.5	15
25	Reversal of Alopecia Universalis by Tofacitinib: A Case Report. <i>Annals of Internal Medicine</i> , 2016, 165, 750.	2.0	14
26	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021, 60, 256-262.	0.9	14
27	The development of arthritis and antinuclear antibodies correlate with serum 25-hydroxyvitamin D levels in patients with leprosy. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 2062-2063.	0.5	13
28	Recovery of nail dystrophy potential new therapeutic indication of tofacitinib. <i>Clinical Rheumatology</i> , 2017, 36, 971-973.	1.0	13
29	Total hip and knee joint replacement: perioperative clinical aspects. <i>Einstein (Sao Paulo, Brazil)</i> , 2010, 8, 350-353.	0.3	12
30	Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag. <i>Clinical Rheumatology</i> , 2014, 33, 1347-1349.	1.0	12
31	Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, SÃ£o Paulo, Brazil. <i>Clinical Rheumatology</i> , 2008, 27, 1049-1052.	1.0	11
32	Why do some biologic agents induce psoriasis or psoriasiform lesions?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 168-169.	3.2	11
33	An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata:ÂA case report and a review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2539-2542.	0.2	11
34	(18) F-FDG PET Imaging of Rheumatoid Articular and Extraarticular Synovitis. <i>Journal of Clinical Rheumatology</i> , 2008, 14, 307.	0.5	10
35	Use of rituximab as a treatment for systemic lupus erythematosus: retrospective review. <i>Einstein (Sao) Tj ETQq1 1 0.784314 18 BT /Over</i>	0.3	10
36	Bone health in cerebral palsy and introduction of a novel therapy. <i>Einstein (Sao Paulo, Brazil)</i> , 2015, 13, 555-559.	0.3	9

#	ARTICLE	IF	CITATIONS
37	Difference between Enbrel and Benepali treatment groups in "hepatobiliary disorders"™. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e64-e64.	0.5	9
38	The future landscape of biosimilars in rheumatology: Where we are where we are going. <i>Autoimmunity Reviews</i> , 2019, 18, 203-208.	2.5	9
39	The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations. <i>Lupus</i> , 2021, 30, 1684-1695.	0.8	7
40	Decreased need of large joint replacement in patients with rheumatoid arthritis in a specialized Brazilian center. <i>Clinical Rheumatology</i> , 2011, 30, 549-550.	1.0	6
41	Taxas de retenção de infliximabe e tocilizumabe no período de 3 anos em um hospital brasileiro. <i>Einstein (Sao Paulo, Brazil)</i> , 2013, 11, 492-494.	0.3	6
42	Atopic dermatitis: Tofacitinib, an option for refractory disease. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3243-3246.	0.2	6
43	Full histological and clinical regression of morphea with tofacitinib. <i>Clinical Rheumatology</i> , 2020, 39, 2827-2828.	1.0	6
44	Diagnosis of growing pains in a Brazilian pediatric population: a prospective investigation. <i>Einstein (Sao Paulo, Brazil)</i> , 2010, 8, 430-432.	0.3	5
45	Biosimilars in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 710.	0.6	5
46	Partnership for productive development of biosimilar products: perspectives of access to biological products in the Brazilian market. <i>Einstein (Sao Paulo, Brazil)</i> , 2018, 16, eRW4175.	0.3	5
47	Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America. <i>MAbs</i> , 2018, 10, 827-842.	2.6	5
48	Lupus low disease activity (SLE) in patients treated with belimumab: a single-center real-life experience (2016-2019). <i>Clinical Rheumatology</i> , 2021, 40, 923-927.	1.0	5
49	Tofacitinib-induced remission simultaneously in arthritis and vitiligo. <i>European Journal of Rheumatology</i> , 2021, 8, 55-56.	1.3	5
50	Fibromyalgia: An update and immunological aspects. <i>Current Pain and Headache Reports</i> , 2008, 12, 321-326.	1.3	4
51	Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy. <i>Rheumatology</i> , 2014, 53, 957-958.	0.9	4
52	Quando anti-TNF não obtém sucesso, anti-IL-12/23 é opção alternativa na psoríase e na artrite psoriásica. <i>Revista Brasileira De Reumatologia</i> , 2014, 54, 247-249.	0.8	4
53	Ganciclovir-resistant, cytomegalic interstitial lung disease in a patient with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2007, 26, 1753-1755.	1.0	3
54	Anti-interleukin 6: first line in rheumatoid arthritis?. <i>Clinical Rheumatology</i> , 2009, 28, 877-879.	1.0	3

#	ARTICLE	IF	CITATIONS
55	When anti-TNF fails, anti-IL12-23 is an alternate option in psoriasis and psoriatic arthritis. Revista Brasileira De Reumatologia, 2014, 54, 247-249.	0.7	3
56	Knowledge gap about immune checkpoint inhibitors among rheumatologists and medical students: a survey. Rheumatology International, 2021, 41, 939-942.	1.5	3
57	Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review. Future Science OA, 2021, 7, FSO655.	0.9	3
58	Uma nova era na terapia em psoríase e artrite psoriática: novos mecanismos de ação e a introdução de biossimilares. Revista Brasileira De Reumatologia, 2015, 55, 469-470.	0.8	2
59	Facing up to biosimilar agents – the ACR position. Nature Reviews Rheumatology, 2015, 11, 322-324.	3.5	2
60	The NICE position on indications for biologics and biosimilars. Nature Reviews Rheumatology, 2016, 12, 255-256.	3.5	2
61	Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms. Drug Design, Development and Therapy, 2018, Volume 12, 2775-2783.	2.0	2
62	Clinical evidence guidelines in systemic lupus erythematosus: reevaluation. Annals of the Rheumatic Diseases, 2019, 78, e119-e119.	0.5	2
63	A presença da reumatologia brasileira no GRAPPA (Group for Research and Assessment of Psoriasis) Tj ETQq1 1 0.784314 rgBT /Over	0.8	2
64	Is Etaner a new biologic?. Clinical and Experimental Rheumatology, 2016, 34, 954.	0.4	2
65	Chronic Inguinal Lymphadenitis in a Patient With Rheumatoid Arthritis Being Treated With Tofacitinib. Journal of Clinical Rheumatology, 2020, 26, e138-e139.	0.5	1
66	Failure to Control Progression of Rheumatoid Arthritis After a Decade of Biologic Therapy. Journal of Rheumatology, 2012, 39, 2049-2050.	1.0	0
67	Comparison of thromboprophylaxis patterns in arthroplasty in public and private hospitals. Einstein (Sao Paulo, Brazil), 2015, 13, 410-416.	0.3	0
68	Summary of baricitinib effect on patient-reported outcomes (PROs) in methotrexate-inadequate responder patient population. Rheumatology, 2018, 57, .	0.9	0
69	Negative specificity for DSF70 in ANA positive leprosy sera. Clinical Rheumatology, 2019, 38, 2953-2955.	1.0	0
70	A Critical Analysis of the First Latin American Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2022, 28, e312-e316.	0.5	0